ACE-031 1MG

Almost everything else in this catalogue is an agonist. ACE-031 is not. It binds a receptor and turns it on. ACE-031 is the reverse: a piece of a receptor floating free in the circulation, catching the signalling molecules before they arrive. That inversion accounts for everything below.

Specification Table

What Kind of Molecule Is ACE-031?

ACE-031 is a fusion protein, which means two pieces of protein joined into one chain that does not exist in nature.

The first piece is the part of activin receptor type IIB that normally sits outside the cell and catches ligands. Cut from the membrane it still binds.

The second piece is the Fc region of a human antibody, doing two jobs at once. Antibody Fc regions circulate for weeks rather than minutes, and they pair up, which means the fusion arrives as a dimer carrying two binding sites.

The result is a molecule that soaks up growth factors and does nothing with them.

That is a completely different thing from a peptide agonist, and the difference runs through the handling section as well as the pharmacology. This is a large glycosylated protein produced in cells, not a synthesised chain, and it behaves like an antibody in solution.

Why Does Low Selectivity Matter Here?

The ACE-031 design intent was myostatin. What the ectodomain actually binds is a family.

Activin receptor type IIB is a receptor for several ligands, so an ectodomain built from it catches several ligands, including activins and GDF-11 alongside the intended target.

For a receptor sitting on a membrane, that breadth is ordinary biology and nothing to remark on. For a trap released into the circulation it means everything the receptor could have bound is now being removed from circulation instead.

This is the mirror image of the selectivity problem that appears elsewhere in this catalogue. A non-selective agonist activates several pathways. A non-selective trap silences several at once, and you find out which ones only afterwards.

It also makes attribution harder in a specific way. With an agonist you can sometimes narrow things down with a selective antagonist. With a trap you would need to know which of the absorbed ligands mattered, and the natural experiment of removing one at a time is not available.

What happened in the clinic is the clearest illustration of the problem anyone could ask for.

What Stopped the Programme?

The ACE-031 trial stopped after its second regimen.

Nosebleeds, bleeding gums and small dilated surface vessels.

Campbell and colleagues published the results in 2017, some years after the programme ended, and reported trends toward higher lean mass and bone mineral density and lower fat mass, none of which reached statistical significance.

The explanation that emerged points back at the selectivity question. The trap also absorbs BMP-9, and BMP-9 signalling is part of what keeps blood vessels stable.

There is independent support for that link. People born with loss-of-function variants in the BMP-9 pathway develop vascular malformations and bleeding, which is the same picture the trial produced pharmacologically.

I find this the most interesting thing about the compound, and it is entirely absent from the listings that sell it.

A researcher planning work here should know that the vascular finding is not an unexplained oddity. It is the predicted consequence of a trap that catches more than it was aimed at, and any design should account for the possibility of off-target sequestration rather than assume myostatin is the only thing being removed.

What Should the Certificate Show?

ACE-031 identity, which for a fusion protein means confirming both halves and the junction between them.

The expression system, because a protein produced in mammalian cells and one produced in a bacterial system are different articles with different glycosylation.

Glycosylation profile, or at least a statement that somebody looked at it. Fc function and half life both depend on it.

Purity by size exclusion chromatography rather than only by reverse phase, since aggregation is the failure mode that matters on a dimeric protein.

Aggregate content, as a number rather than as a reassurance.

Endotoxin, with the method named. A protein from a cell culture carries an endotoxin question that a synthetic peptide does not.

Host cell protein and residual DNA, both as figures.

Lot number and manufacturing date.

A certificate written to a synthetic peptide template will list a sequence purity and stop, and none of the fields above will be on it. That is the wrong document for this article.

What Does One Milligram of a Fusion Protein Mean?

One milligram of ACE-031 is far less than one milligram of a peptide, and the gap is larger than most people expect.

An Fc fusion of this kind is a glycosylated dimer somewhere in the region of 75 to 80 kilodaltons, and the exact figure depends on the glycans. Take 78 as a working figure and one milligram is around 13 nanomoles.

For comparison, a 10 milligram vial of a 2000 dalton peptide holds 5 micromoles, which is roughly four hundred times more molecules.

So a 1 milligram vial of this article is a small quantity in molar terms even though the mass sounds ordinary.

Binding stoichiometry makes it smaller again. ACE-031 works by occupying ligand, one binding event at a time, so the useful quantity is set by how much ligand there is rather than by how potent the trap is.

That is a different relationship from an agonist, where a catalytic amount can drive a large response. A trap is consumed by what it catches.

Anyone sizing an experiment should calculate the molar quantity of target ligand present in the system and compare it against the 13 nanomoles in the vial, rather than reasoning from a concentration that worked for a peptide.

Glycosylation adds one more wrinkle, which is that the mass is a distribution rather than a single figure, so the molar calculation is approximate no matter how carefully it is done.

A related point that follows from the trap arithmetic.

Because a trap is consumed by what it binds, the useful working question is not what concentration to reach but how long the trap stays available.

That is a different experimental variable from anything else in this catalogue, and it is one the vial size sets directly.

A design running over days rather than hours needs to account for the trap being used up, and a single vial may not carry it.

Why Was Myostatin a Target at All?

Because of cattle, and then because of mice.

Certain cattle breeds carry a natural loss-of-function variant and are visibly more muscular than their relatives, a phenotype known long before anyone knew the gene.

McPherron and colleagues identified the gene in 1997. Mice lacking it developed dramatically more muscle mass, which established myostatin as a negative regulator of muscle growth.

Later work by the same group showed that a soluble form of the receptor produced a similar effect pharmacologically, which is the direct ancestor of ACE-031.

That is an unusually clean target rationale. A gene, a natural knockout phenotype in two species, a mouse knockout, and a pharmacological reproduction of the phenotype.

It is also a good illustration of the gap between a clean rationale and a working compound.

The genetic evidence concerns removal of one ligand across a whole lifetime. The pharmacological approach removes several ligands intermittently in an adult animal, and those are not the same intervention even when the intended target is the same.

The vascular findings that stopped the clinical programme sit precisely in that gap, and they were not predictable from the genetics because the genetics only ever removed myostatin.

The target itself has not gone away. Other approaches to the same pathway have continued, and some of them narrowed the ligand specificity precisely because of what happened here.

How Should the Vial Be Handled?

Handle it as a protein, because it is one, and protein rules are stricter than peptide rules on every axis.

Sealed lyophilised material holds at minus 20 degrees Celsius or below, dark and dry.

Bring the vial to ambient temperature before opening, then reconstitute by running the diluent down the wall and letting the cake dissolve on its own.

Do not vortex ACE-031, do not shake it, and do not pipette it vigorously. A dimeric protein at an air-liquid interface unfolds and aggregates, and the damage is invisible.

Do not freeze the reconstituted solution. Freeze-thaw is the most reliable way to destroy a protein preparation.

Aliquot on first reconstitution and keep working stocks refrigerated for short periods rather than frozen.

Use low-binding consumables at every step. Adsorption on a protein at assay concentrations is substantial.

Run size exclusion chromatography on anything held more than a few days, and keep the trace.

Record lot, expression system, aggregate content if measured, diluent, storage temperature and reconstitution date.

Expression system belongs on that list. It changes what the molecule is, which is a different thing from how it was made.

Published Literature

Selected references on the clinical trial that ended the programme, on animal work with the same construct and on protein storage generally.

1. Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, et al. Muscle and Nerve. 2017;55(4):458-464. DOI: 10.1002/mus.25268
2. Lee SJ, McPherron AC. Proceedings of the National Academy of Sciences. 2001;98(16):9306-9311. DOI: 10.1073/pnas.151270098
3. McPherron AC, Lawler AM, Lee SJ. Nature. 1997;387(6628):83-90. DOI: 10.1038/387083a0
4. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Pharmaceutical Research. 2010;27(4):544-575. DOI: 10.1007/s11095-009-0045-6

Frequently Asked Questions